Erlangen, Germany (PRWEB) February 27, 2015
nUro, Inc. (“the Company”) announced today that it is opening a German subsidiary in the Erlangen Medical Valley Center, located near Nurnberg, Bavaria. As a medical device manufacturer focused on advanced neuromodulation solutions for a variety of disease, the Company views the Medical Valley as an ideal environment to advance its technology and to collaborate with renowned physicians and scientists.
“We are very glad to welcome nUro, Inc. within the Medical Valley-Community,” said Jörg Trinkwalter, Member of the Executive Board of Medical Valley Association. “Medical Valley is an internationally leading cluster in the medical engineering sector. The area is home to highly specialized research facilities, global players, and many upcoming companies – and this mixture, in our opinion, is the optimal ecosystem for nUro to grow their business in Europe.”
Currently, the Company has US manufacturing operations and is adapting its CE Marked Synapse™ system to a wireless neurostimulation system for the treatment of overactive bladder (OAB). OAB is a urological condition related to problems with urinary urgency, frequency, and incontinence that affects roughly 16.5% of the adult population in both the United States and Europe. Neurostimulation of the posterior tibial nerve, located above the ankle in the patient’s lower leg, recently emerged as an effective alternative therapy to unsuccessful behavioral modifications, drug treatments, and irreversible surgical approaches. Patients will be able to treat themselves at home and at their own convenience to achieve and sustain clinical benefits of this therapy.
The newly launched nUro, Inc. German subsidiary will serve to support clinical operations as the company completes clinical studies at top German hospitals. “Germany is considered a world leader in the development and adoption of advanced medical technologies,” said Dipl. Ing. Hartmut Spitaels, MBA, Executive Chairman and General Manager of European Operations. “In addition to a supportive and forward-thinking regulatory environment, the Company hopes to access a rich pool of medical device talent.”
nUro, Inc., the US Parent Company, is currently in the process of filing a Registration Statement with the US Securities and Exchange Commission for the purpose of becoming a fully reporting Public Company initially trading on the US OTC Markets QB Stock Exchange. The Company expects to be trading by August 1, 2015. Also during 2015, the Company will file for a listing to begin trading its Shares on one of the major German Stock Exchanges.
About nUro, Inc. – nUro, Inc. was founded upon a plan to develop and manufacture closed loop neurostimulation technologies. It has the experienced leadership of Will Rosellini and Hartmut Spitaels to bring this platform medical device to market for the treatment of various chronic conditions. The Company arose from the development of viable clinical programs acquired from Medtronic, developed via SBIR funding at Rosellini Scientific, and finalized via the acquisition of Synaptix, a vertically integrated medical device manufacturing company with a CE Marked deep brain stimulator. This 16-channel recording and stimulation platform has been deployed in clinical studies for the treatment of movement disorders and atrial fibrillation. In addition, the Company has developed a wireless version of the device for use in the peripheral nervous system, most notably the posterior tibial nerve for the treatment of urological disorders. nUro, Inc. has now produced and tested its device conforming to good manufacturing practice in its class 10,000 cleanroom. It is in the midst of a number of controlled clinical trials.
For more information on Nuro and the current offering, please visit our website at http://www.nurocorp.com